Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Duodenal Laser Ablation for Treatment of Type 2 Diabetes: Results of First in Human Study

V. Kovarova, I. Lankova, E. Machytka, K. Knotkova, H. Kratochvílová, M. Beneš, J. Spicak, A. Vasura, E. Goldin, G. Munter, T. Zima, M. Mraz, H. Dagan, B. Levy, M. Haluzik, J. Kral

. 2025 ; 13 (5) : 750-758. [pub] 20250220

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015556

Grantová podpora
Digma Medical

BACKGROUND: Diabetes mellitus (DM) significantly impacts global health and economies. Despite various therapies, managing DM remains challenging. Bariatric surgery has shown efficacy in obese patients with type 2 diabetes mellitus (T2DM), but its utilization remains low. Innovative, less invasive endoscopic approaches such as duodenal mucosal resurfacing show potential in treating T2DM. This article presents the results of a First in Human (FIH) study using a duodenal submucosal laser ablation investigational device for T2DM treatment. METHODS: A prospective, single-arm, open-label study evaluated the safety and efficacy of the Digma System Endoscopic procedure for duodenal submucosal laser ablation in consecutive enrolled T2DM patients. RESULTS: The study was conducted from July 2017 to December 2020 and enrolled 31 patients for the Digma System Endoscopic procedure. The Dose Escalation Cohort (DEC) used sub-therapeutic laser doses for training and safety. The Treatment Cohort (TC) of 25 patients received therapeutic doses, resulting in HbA1c reductions of -0.6% at 6 months (p = 0.014) and -0.4% at 12 months (p = 0.062). Fasting glucose dropped 17.3 mg/dL (p = 0.173) at 6 months and 28 mg/dL (p = 0.022) at 12 months. Post-prandial glucose improvements were also observed. HOMA-IR improved at 3 and 6 months. PAGI-SYM and PAGI-QOL showed stable to slightly improved GI symptoms and quality of life. Two severe adverse events were unrelated to the procedure. CONCLUSION: The study demonstrates the safety, feasibility, and potential efficacy of the Digma System Endoscopic procedure. Evidence suggests improvements in HbA1c, fasting and post-prandial glucose, and HOMA-IR levels could be attributed to the Digma System Endoscopic procedure.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015556
003      
CZ-PrNML
005      
20250731091054.0
007      
ta
008      
250708s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ueg2.12762 $2 doi
035    __
$a (PubMed)39976927
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kovarova, Viktorie $u Department of Diabetes, Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
245    10
$a Duodenal Laser Ablation for Treatment of Type 2 Diabetes: Results of First in Human Study / $c V. Kovarova, I. Lankova, E. Machytka, K. Knotkova, H. Kratochvílová, M. Beneš, J. Spicak, A. Vasura, E. Goldin, G. Munter, T. Zima, M. Mraz, H. Dagan, B. Levy, M. Haluzik, J. Kral
520    9_
$a BACKGROUND: Diabetes mellitus (DM) significantly impacts global health and economies. Despite various therapies, managing DM remains challenging. Bariatric surgery has shown efficacy in obese patients with type 2 diabetes mellitus (T2DM), but its utilization remains low. Innovative, less invasive endoscopic approaches such as duodenal mucosal resurfacing show potential in treating T2DM. This article presents the results of a First in Human (FIH) study using a duodenal submucosal laser ablation investigational device for T2DM treatment. METHODS: A prospective, single-arm, open-label study evaluated the safety and efficacy of the Digma System Endoscopic procedure for duodenal submucosal laser ablation in consecutive enrolled T2DM patients. RESULTS: The study was conducted from July 2017 to December 2020 and enrolled 31 patients for the Digma System Endoscopic procedure. The Dose Escalation Cohort (DEC) used sub-therapeutic laser doses for training and safety. The Treatment Cohort (TC) of 25 patients received therapeutic doses, resulting in HbA1c reductions of -0.6% at 6 months (p = 0.014) and -0.4% at 12 months (p = 0.062). Fasting glucose dropped 17.3 mg/dL (p = 0.173) at 6 months and 28 mg/dL (p = 0.022) at 12 months. Post-prandial glucose improvements were also observed. HOMA-IR improved at 3 and 6 months. PAGI-SYM and PAGI-QOL showed stable to slightly improved GI symptoms and quality of life. Two severe adverse events were unrelated to the procedure. CONCLUSION: The study demonstrates the safety, feasibility, and potential efficacy of the Digma System Endoscopic procedure. Evidence suggests improvements in HbA1c, fasting and post-prandial glucose, and HOMA-IR levels could be attributed to the Digma System Endoscopic procedure.
650    _2
$a lidé $7 D006801
650    12
$a diabetes mellitus 2. typu $x chirurgie $x krev $7 D003924
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a duodenum $x chirurgie $7 D004386
650    _2
$a prospektivní studie $7 D011446
650    12
$a laserová terapie $x metody $x škodlivé účinky $x přístrojové vybavení $7 D053685
650    _2
$a glykovaný hemoglobin $x analýza $x metabolismus $7 D006442
650    _2
$a krevní glukóza $x analýza $x metabolismus $7 D001786
650    _2
$a výsledek terapie $7 D016896
650    _2
$a dospělí $7 D000328
650    _2
$a střevní sliznice $x chirurgie $7 D007413
650    _2
$a senioři $7 D000368
650    _2
$a kvalita života $7 D011788
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lankova, Ivana $u Department of Diabetes, Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Machytka, Evzen $u Department of Hepatogastroenterology, Transplantation Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Knotkova, Katerina $u Department of Hepatogastroenterology, Transplantation Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Kratochvílová, Helena $u Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Beneš, Marek $u Department of Hepatogastroenterology, Transplantation Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Spicak, Julius $u Department of Hepatogastroenterology, Transplantation Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Vasura, Adam $u Department of Gastroenterology, Hepatology and Pancreatology, Internal and Cardiologic Clinic, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Goldin, Eran $u Shaare Zedek Medical Center, Digestive Disease Institute, Jerusalem, Israel
700    1_
$a Munter, Gavriel $u Endocrinology and Metabolism, Shaare Zedek Medical Center, Jerusalem, Israel
700    1_
$a Zima, Tomas $u Institute of Medical Biochemistry and Laboratory Diagnostics of the General University Hospital and of the First Faculty of Medicine of Charles University, Prague, Czech Republic
700    1_
$a Mraz, Milos $u Department of Diabetes, Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Dagan, Hila $u Digma Medical, Givat Shmuel, Israel
700    1_
$a Levy, Brian $u Digma Medical, Givat Shmuel, Israel
700    1_
$a Haluzik, Martin $u Department of Diabetes, Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Kral, Jan $u Department of Hepatogastroenterology, Transplantation Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Department of Internal Medicine, Second Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00188834 $t United European gastroenterology journal $x 2050-6414 $g Roč. 13, č. 5 (2025), s. 750-758
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39976927 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091048 $b ABA008
999    __
$a ok $b bmc $g 2366415 $s 1252681
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 13 $c 5 $d 750-758 $e 20250220 $i 2050-6414 $m United European gastroenterology journal $n United European Gastroenterol J $x MED00188834
GRA    __
$p Digma Medical
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace